Patent: 10,030,238
✉ Email this page to a colleague
Summary for Patent: 10,030,238
| Title: | Recombinant clostridium botulinum neurotoxins |
| Abstract: | The invention provides a nucleic acid sequence comprising a sequence of contiguous nucleotides, wherein said sequence of contiguous nucleotides has at least 90% sequence identity to the nucleic acid sequence of SEQ ID NO: 1, and wherein said sequence of contiguous nucleotides encodes a single-chain BoNT/E1 protein. The present invention also provides methods for producing soluble single-chain BoNT/E1 protein in an E. coli host cell, together with methods for producing soluble di-chain BoNT/E1 protein. |
| Inventor(s): | Cossins; Aimee (Abingdon, GB), Beard; Matthew (Abingdon, GB), Marks; Philip (Wrexham, GB) |
| Assignee: | IPSEN BIOINNOVATION LIMITED (Abingdon, Oxfordshire, GB) IPSEN BIOPHARM LIMITED (Slough, Berkshire, GB) |
| Application Number: | 14/427,234 |
| Patent Claims: | see list of patent claims |
Details for Patent 10,030,238
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
|---|---|---|---|---|---|---|---|
| Merck Sharp & Dohme Llc | ZOSTAVAX | zoster vaccine live | For Injection | 125123 | May 25, 2006 | 10,030,238 | 2033-10-31 |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
